Side-by-side · Research reference
GDF-8vsHumanin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/48 cited
BAnimal-StrongHUMAN-REVIEWED14/52 cited
GDF-8
TGF-β Superfamily · Negative Muscle Regulator
15–20%Muscle mass gain (MSTN−/−)
Not administered — research target for inhibition
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
01Mechanism of Action
Parameter
GDF-8
Humanin
Primary target
Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026
Pathway
MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Downstream effect
Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026Iglesias 2026
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Feedback intact?
Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Origin
Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Antibody development
—
Not reported in animal models
02Dosage Protocols
Parameter
GDF-8
Humanin
Clinical use
None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans
Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.
—
Inhibition strategies
Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)
—
VLP immunogen (MS2.87-97)
Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026
Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026
—
Dual immunization (MSTN + Activin A)
Combined active immunization in GH-deficient miceMansoor 2026
Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026
—
Gene editing outcomes
Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock
Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.
—
Standard experimental dose (HNG)
—
4 mg/kg IP (rat)
Most common dose in rodent models.
Ex vivo bone culture
—
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
Frequency
—
Daily (IP)
Duration
—
8–12 weeks in animal studies
Human data
—
None — no clinical trials reported
Analog (HNG)
—
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
03Metabolic / Fat Loss Evidence
Parameter
GDF-8
Humanin
Primary mechanism
MSTN loss-of-function reduces fat accumulation independent of muscle mass effects
—
Human genetic evidence
Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026
—
Animal model outcomes
VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026
—
Adipose-muscle crosstalk
MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026
—
Age-related effects
MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation
—
Direct fat loss evidence
—
None
Mechanism overlap
—
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
04Side Effects & Safety
Parameter
GDF-8
Humanin
Genetic null phenotype
No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026
—
Antibody cross-reactivity risk
Non-selective inhibitors may block GDF11, affecting cardiac and neural function
—
VLP immunotherapy safety
No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026
—
Pleiotropic effects (gene editing)
MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare
—
Assay variability
Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026
—
Animal model safety
—
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
Human safety data
—
None — no clinical trials
Theoretical fibrillation risk
—
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
Injection site reaction
—
Not reported in animal studies (IP route)
Reproductive safety
—
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
Absolute Contraindications
GDF-8
- ·Not applicable — MSTN is not administered as a therapeutic agent
Humanin
- ·Unknown — no human data
Relative Contraindications
GDF-8
- ·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
05Administration Protocol
Parameter
GDF-8
Humanin
1. Research context only
GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
2. Inhibition strategies
Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
3. VLP immunization protocol (animal model)
MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026
Daily administration in animal studies. Optimal timing not characterized.
4. Gene editing considerations
CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
5. Human use
—
No FDA approval, no IND, no clinical trials. Experimental research tool only.
06Stack Synergy
GDF-8
— no documented stacks
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling